Effects of Adjuvants in a Rabies-Vectored Ebola Virus Vaccine on Protection From Surrogate Challenge
Ebola virus is the primary contributor to the global threat of filovirus severe hemorrhagic fever, and Ebola virus disease has a case fatality rate of 50-90%. An inactivated, bivalent filovirus/rabies virus vaccine, FILORAB1, consists of recombinant rabies virus virions expressing the Ebola virus glycoprotein. FILORAB1 is immunogenic and protective from Ebola virus challenge in mice and non-human primates, and protection is enhanced when formulated with toll-like receptor 4 agonist Glucopyranosyl lipid adjuvant (GLA) in a squalene oil-in-water emulsion (SE). Through an adjuvant comparison in mice, we demonstrate that GLA-SE improves FILORAB1 efficacy by activating the innate immune system and shaping a Th1-biased adaptive immune response. GLA-SE adjuvanted mice and those adjuvanted with the SE component are better protected from surrogate challenge, while Th2 alum adjuvanted mice are not. Additionally, the immune response to FILORAB1 is long-lasting, as exhibited by highly-maintained serum antibody titers and long-lived cells in the spleen and bone marrow.
Yankowski, Catherine; Kurup, Drishya; Wirblich, Christoph; and Schnell, Matthias J., "Effects of Adjuvants in a Rabies-Vectored Ebola Virus Vaccine on Protection From Surrogate Challenge" (2023). Department of Microbiology and Immunology Faculty Papers. Paper 172.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
This article is the author’s final published version in npj Vaccines, Volume 8, Issue 1, February 2023, Article number 10.
The published version is available at https://doi.org/10.1038/s41541-023-00615-z. Copyright © Yankowski et al.